Anacor Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing small-molecule therapeutics derived from its boron chemistry platform. The Company has discovered, synthesized and developed eight molecules that are in development. Its lead product candidates include two topically administered dermatologic compounds tavaborol and AN2728. The Company has discovered three investigational compounds that it has out-licensed for further development. The compound is licensed to Eli Lilly and Company (Lilly) for the treatment of an animal health indication. The second compound, AN5568 is indicated for the potential treatment of human African trypanosomiasis (HAT, or sleeping sickness) and the third compound is licensed to GlaxoSmithKline LLC (GSK) for development in tuberculosis (TB).It also has a pipeline of other topical and systemic boron-based compounds which include, AN2718, AN2898 and AN3365.